title: Peroral immunization of microencapsulated human VP8 in combination with cholera toxin induces intestinal antibody responses.
abstract: To develop an orally delivered subunit vaccine for rotavirus infection, a trypsin cleavage product of VP4, recombinant VP8*, was expressed in Escherichia coli. The recombinant VP8* (rVP8*), purified by affinity chromatography, was reactive against human rotavirus positive serum in Western-blot analysis. To further evaluate the immunogenicity of the oral-delivered rVP8*, it was encapsulated with alginate-microsphere and administered in combination with cholera toxin (CT) as a mucosal adjuvant perorally into mice. The ELISPOT assay showed that the number of rVP8*-specific IgG1 antibody secreting cells increased about 3-fold and about 2-fold in spleen and Peyer's patch, respectively as compared to non-immune mice. In addition, the number of rVP8*-specific IgA antibody secreting cells increased about 2-fold in Peyer's patch. Finally, rVP8*-specific IgA antibody response was significantly enhanced in the intestinal fluids from the mice immunized perorally with encapsulated rVP8* and CT. Taken together, these results indicate that rVP8* possessed proper immunogenicity and it would be potentially useful as a subunit vaccine against rotavirus-associated disease through peroral immunization.
authors.affiliation: Department of Life Science, Sogang University, Seoul, Korea.
authors.forename: D K
authors.initials: DK
authors.lastname: Kang
authors.forename: P H
authors.initials: PH
authors.lastname: Kim
authors.forename: E J
authors.initials: EJ
authors.lastname: Ko
authors.forename: J Y
authors.initials: JY
authors.lastname: Seo
authors.forename: S Y
authors.initials: SY
authors.lastname: Seong
authors.forename: Y H
authors.initials: YH
authors.lastname: Kim
authors.forename: I C
authors.initials: IC
authors.lastname: Kwon
authors.forename: S Y
authors.initials: SY
authors.lastname: Jeong
authors.forename: J M
authors.initials: JM
authors.lastname: Yang
mesh_terms: D000276:Adjuvants, Immunologic; D000284:Administration, Oral; D000464:Alginates; D000818:Animals; D015153:Blotting, Western; D002213:Capsid / Q000737:chemistry / Q000276:immunology*; D036022:Capsid Proteins; D002772:Cholera Toxin / Q000276:immunology; D004339:Drug Compounding; D004797:Enzyme-Linked Immunosorbent Assay; D004926:Escherichia coli; D006801:Humans; D007114:Immunization; D007070:Immunoglobulin A / Q000276:immunology*; D007413:Intestinal Mucosa / Q000276:immunology; D007422:Intestines / Q000276:immunology*; D051379:Mice; D008855:Microscopy, Electron, Scanning; D008863:Microspheres; D011994:Recombinant Proteins / Q000276:immunology; D012400:Rotavirus Infections / Q000517:prevention & control*; D014357:Trypsin; D014765:Viral Vaccines / Q000008:administration & dosage*
chemical_list: D000276:Adjuvants, Immunologic; D000464:Alginates; D036022:Capsid Proteins; D007070:Immunoglobulin A; D011994:Recombinant Proteins; C060339:VP4 protein, Rotavirus; D014765:Viral Vaccines; D002772:Cholera Toxin; D014357:Trypsin